5-aza-2′-deoxycitidine inhibits cell proliferation, extracellular matrix formation and Wnt/β-catenin pathway in human uterine leiomyomas
Open Access
- 8 July 2021
- journal article
- research article
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 19 (1) , 1-10
Abstract
Background: Uterine leiomyoma is a benign tumor with unclear pathogenesis and inaccurate treatment. This tumor exhibits altered DNA methylation related to disease progression. DNMT inhibitors as 5-aza-2′-deoxycytidine (5-aza-CdR), have been suggested to treat tumors in which DNA methylation is altered. We aimed to evaluate whether DNA methylation reversion with 5-aza-CdR reduces cell proliferation and extracellular matrix (ECM) formation in uterine leiomyoma cells to provide a potential treatment option. Methods: Prospective study using uterine leiomyoma and adjacent myometrium tissues and human uterine leiomyoma primary (HULP) cells (n = 16). In tissues, gene expression was analyzed by qRT-PCR and DNMT activity by ELISA. Effects of 5-aza-CdR treatment on HULP cells were assessed by CellTiter, western blot, and qRT-PCR. Results: DNMT1 gene expression was higher in uterine leiomyoma vs myometrium. Similarly, DNMT activity was greater in uterine leiomyoma and HULP cells (6.5 vs 3.8 OD/h/mg; 211.3 vs 63.7 OD/h/mg, respectively). After 5-aza-CdR treatment on HULP cells, cell viability was reduced, significantly so at 10 μM (85.3%). Treatment with 10 μM 5-aza-CdR on HULP cells significantly decreased expression of proliferation marker PCNA (FC = 0.695) and of ECM proteins (COLLAGEN I FC = 0.654; PAI-1, FC = 0.654; FIBRONECTIN FC = 0.733). 5-aza-CdR treatment also decreased expression of Wnt/β-catenin pathway final targets, including WISP1 protein expression (10 μM, FC = 0.699), c-MYC gene expression (2 μM, FC = 0.745 and 10 μM, FC = 0.728), and MMP7 gene expression (5 μM, FC = 0.520 and 10 μM, FC = 0.577). Conclusions: 5-aza-CdR treatment inhibits cell proliferation, ECM formation, and Wnt/β-catenin signaling pathway targets in HULP cells, suggesting that DNA methylation inhibition is a viable therapeutic target in uterine leiomyoma.Keywords
Funding Information
- Instituto de Salud Carlos III (PI18/00323, CP19/00149, CP20/00120)
- Conselleria d'Educació, Investigació, Cultura i Esport (PROMETEO/2018/137, ACIF/2019/139, APOSTD/2020/123)
- Ministerio de Educación, Cultura y Deporte (FPU18/03735)
This publication has 59 references indexed in Scilit:
- Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growthProceedings of the National Academy of Sciences, 2013
- Genome-Wide DNA Methylation Analysis Reveals a Potential Mechanism for the Pathogenesis and Development of Uterine LeiomyomasPLOS ONE, 2013
- 5-Aza-2′-deoxycytidine Leads to Reduced Embryo Implantation and Reduced Expression of DNA Methyltransferases and Essential Endometrial GenesPLOS ONE, 2012
- Wnt/β-Catenin Signaling and DiseaseCell, 2012
- 1,25-Dihydroxyvitamin D3 Treatment Shrinks Uterine Leiomyoma Tumors in the Eker Rat Model1Biology of Reproduction, 2012
- Genome-Wide DNA Methylation Indicates Silencing of Tumor Suppressor Genes in Uterine LeiomyomaPLOS ONE, 2012
- DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancerGenome Research, 2011
- Differential expression of the CCN family member WISP-1, WISP-2 and WISP-3 in human colorectal cancer and the prognostic implicationsInternational Journal of Oncology, 2010
- Human myometrium and leiomyomas express gonadotropin-releasing hormone 2 and gonadotropin-releasing hormone 2 receptorFertility and Sterility, 2007
- Diet and uterine myomasObstetrics & Gynecology, 1999